Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clinical Microbiology Reviews
2000; 13: 302–317.
Zuber PL, et al.
Sustaining GAVI-supported vaccine introductions in resource-poor countries. Vaccine
2011; 29: 3149–3154.
Kelly DF, Moxon ER, Pollard AJ.
Haemophilus influenzae type b conjugate vaccines. Immunology
2004; 113: 163–174.
Eskola J, et al.
A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. New England Journal of Medicine
1990; 323: 1381–1387.
Ward J, et al.
Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. New England Journal of Medicine
1990; 323: 1393–1401.
WHO. WHO Position Paper on Haemophilus influenzae type b conjugate vaccines
Weekly Epidemiological Record
2006; 81: 445–452.
Capeding MR, et al.
The immunogenicity of three Haemophilus influenzae type B conjugate vaccines after a primary vaccination series in Philippine infants. American Journal of Tropical Medicine and Hygiene
1996; 55: 516–.520.25
Clemens J, et al.
Evaluating new vaccines for developing countries. Efficacy or effectiveness?
Journal of American Medical Association
1996; 275: 390–397.
Griffiths UK, Miners A. Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature. Expert Review of Pharmacoecononics and Outcomes Research
2009; 9: 333–346.
Clark A, Sanderson C. Timing of children's vaccinations in 45 low-income and middle income countries: an analysis of survey data. Lancet
2009; 373: 1543–1549.
Fitzwater SP, et al.
Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries. Human Vaccines
2010; 6: 810–818.
Obonyo CO, Lau J. Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis. European Journal of Clinical Microbiology and Infectious Diseases
2006; 25: 90–97.
O'Loughlin RE, et al.
Methodology and measurement of the effectiveness of Haemophilus influenzae type b vaccine: systematic review. Vaccine
2010; 28: 6128–6136.
Liberati A, et al.
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine
2009; 6: e1000100.
Dickersin K, et al.
Development of the Cochrane Collaboration's CENTRAL Register of controlled clinical trials. Evaluation & the Health Professions
2002; 25: 38–64.
Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, March 2011.
Cherian T. Describing the epidemiology and aetiology of bacterial pneumonia in children: an unresolved problem. Journal of Health Population and Nutrition
2005; 23: 1–5.
Shann F. Determining etiology of pneumonia. Pediatric Infectious Disease Journal
1995; 14: 920–921.
Obaro SK, Madhi SA. Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining?
Lancet Infectious Diseases
2006; 6: 150–161.
Mulholland K, et al.
Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. Lancet
1997; 349: 1191–1197.
Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care Meta-analysis in Context: BMJ Books, 2001.
Higgins JP, et al.
Measuring inconsistency in meta-analyses. British Medical Journal
2003; 327: 557–560.
Peltola H, et al.
Clinical comparison of the Haemophilus influenzae type B polysaccharide diphtheria toxoid and the oligosaccharide-CRM197 protein vaccines in infancy. Archives of Pediatrics & Adolescent Medicine
1994; 148: 620–625.
Santosham M, et al.
The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. New England Journal of Medicine
1991; 25: 1767–1772.
Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa. Expert Review Vaccines
2009; 8: 91–102.
Gessner BD, et al.
Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet
2005; 365: 43–52.
Theodoratou E, et al.
The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality. International Journal of Epidemiology
2010; 39 (Suppl. 1): i172–185.
Baqui AH, et al.
Effectiveness of Haemophilus influenzae type b conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study. Paediatric Infectious Disease Journal
2007; 26: 565–571.
Ward JI, et al.
Invasive Haemophilus influenzae type b disease in Alaska: background epidemiology for a vaccine efficacy trial. Journal of Infectious Diseases
1986; 153: 17–26.
Singleton R, et al.
The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics
2006; 118: e421–429.
Cowgill KD, et al.
Effectiveness of Haemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya. Journal of American Medical Association
2006; 296: 671–678.
Lagos R, et al.
Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet
1998; 351: 1472–1476.
Mangtani P, et al.
Haemophilus influenzae type b disease in HIV-infected children: a review of the disease epidemiology and effectiveness of Hib conjugate vaccines. Vaccine
2010; 28: 1677–1683.
Madhi SA, et al.
Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatric Infectious Disease Journal
2002; 21: 315–321.
Daza P, et al.
The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine
2006; 24: 6232–6239.
Bennett JV, et al. Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era: a global review of incidence, age distributions, and case-fatality rates. WHO/V&B/0218. Geneva: WHO, 2002.
von Gottberg A CC, et al.
Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003–2009. Vaccine
2012; 30: 565–.71
Ramsay ME, et al.
Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. Journal of Infectious Diseases
2003; 188: 481–485.
McVernon J, et al.
Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. British Medical Journal
2004; 329: 655–658.
Black SB, et al.
Efficacy in infancy of oligosaccharide conjugate Haemophilus influenza type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatric Infectious Disease Journal
1991; 10: 97–104.
Booy R, et al.
Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet
1994; 344: 362–366.
Lagos R, et al.
Large scale, postlicensure, selective vaccination of Chilean infants with PRPT conjugate vaccine: Practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatric Infectious Disease Journal
1996; 15: 216–222.
Levine OS, et al.
Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatric Infectious Disease Journal
1999; 18: 1060–1064.
Vadheim CM, et al.
Effectiveness and safety of a Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Kaiser-UCLA Vaccine Study Group. Pediatrics
1993; 92: 272–279.